Mice and Rats for Cancer Research

Taconic Biosciences uniquely combines a broad portfolio of models, including advanced genetically engineered models (GEMs) and humanized mice with integrated IP access, with expertise in oncology model generation and breeding, all with an ecosystem of scientific support designed to always provide our customers with the best solution. Browse our catalog of readily available models for your next oncology study, explore our portfolio of super immunodeficient mice suitable for testing novel oncology drug candidates, or discuss your specific project needs with a scientist. We also have a range of resources to learn more about the exciting advances in oncology research. 

View our Complete List of Mouse and Rat Models for Cancer Research

Use the options below to filter by category and strain type

Please rotate your device to view the full table

Choose different options to see additional models.

 Available from Taconic's cryopreserved repository.

CategoryModelStrain Name (Stock No.)Strain Type
OncologyBlack 6 (B6NTac)C57BL/6NTacInbred
OncologyB6JBomC57BL/6JBomTacInbred
OncologyBALB/cBALB/cAnNTacInbred
OncologyBALB/c BomBALB/cJBomTacInbred
OncologyC3HC3H/HeNTacInbred
OncologyDBA/2DBA/2NTacInbred
OncologyFVBFVB/NTacInbred
OncologyDBA/1DBA/1JBomTacInbred
Oncology129S6C3H/HeNTacInbred
OncologyB6.SJLB6.SJL-Ptprca Adoptive Transfer
Oncologyβ-actin-luc - Model 11977β-actin-lucAdoptive Transfer
OncologyRag2/OT-IRag2/OT-ITCR Transgenic
OncologyRag2/OT-II (11490)Rag2/OT-IITCR Transgenic
Immuno-OncologyJh (C57BL/6)Jh (C57BL/6)Immunodeficient
Immuno-OncologyRag2 - Model RAGN12Rag2 KnockoutImmunodeficient
Immuno-OncologyRag2/Il2rg Double KnockoutRag2/Il2rg KnockoutImmunodeficient
Immuno-OncologyAbb (H2-Ab1) - Model ABBN12Abb KnockoutImmunodeficient
Immuno-OncologyAbb (H2-Ab1) - Model 4026Abb Knockout with PtprcaImmunodeficient
Immuno-OncologyB2m (β2m)B2m Knockout*Immunodeficient
Immuno-OncologyAbb/B2mAbb/B2m Knockout*Immunodeficient
Immuno-OncologyFcer1g (FcRγ) - Model 583Fcer1g (FcRγ)Immunodeficient
Immuno-OncologyFcgr2b (FcγRII) - Model 580Fcgr2b (FcyRII)Immunodeficient
Immuno-OncologyJh (BALB/c)Jh (BALB/c) Immunodeficient
Immuno-OncologyFcer1g - Model 584Fcer1g (FcRγ)Immunodeficient
Immuno-OncologyFcgr2b - Model 579Fcgr2b (FcγRII)Immunodeficient
Immuno-OncologyRag2 - Model 601Rag2 KnockoutImmunodeficient
Immuno-OncologyCIEA BRG mouseRag2/Il2rg Knockout (BRG)Immunodeficient
OncologyNFκB-RE-lucNFκB-RE-lucReporter
OncologyHLA-A2.1C57BL/6 or CB6F1Transgenic
OncologyHLA-A11C57BL/6 or CB6F1Transgenic
OncologyHLA-A1C57BL/6 or CB6F1Transgenic
OncologyHLA-A24C57BL/6 or CB6F1Transgenic
OncologyHLA-B7C57BL/6 or CB6F1Transgenic
OncologyHLA-B44C57BL/6 or CB6F1Transgenic
OncologyAbb Knockout/Transgenic HLA-DR4C57BL/6Transgenic
OncologyStat1 KnockoutN/ATransgenic
OncologyTSG-p53®N/ATransgenic
OncologyPirc RatN/ATransgenic
OncologyInvasive Lobular Breast Cancer ModelN/A 
OncologyBrca1-Associated Breast Cancer ModelN/A 
OncologyFloxed Ink4a/Arf MouseN/A 
OncologyFloxed p53 MouseN/A 
Immuno-OncologyNOG-EXL (hGM-CSF/hIL-3 NOG)13395Immunodeficient
Immuno-OncologyhIL-2 NOG13440Immunodeficient
Immuno-OncologyhIL-15 NOG13683Immunodeficient
Immuno-OncologyhIL-6 NOG13686Immunodeficient
Immuno-OncologyB2m-NOG14957Immunodeficient
Immuno-OncologyFcResolv® NOG19164Immunodeficient
Immuno-OncologyFcResolv® hIL-15 NOG19220Immunodeficient
Immuno-OncologyFcResolv® NOG-EXL21552Immunodeficient
Immuno-OncologyC.B-17 scid Immunodeficient
Immuno-Oncologyscid-beige Immunodeficient
Immuno-OncologyhuNOG-EXL SA (Standard Access) Immunodeficient
Immuno-OncologyhuNOG-EXL EA (Early Access) Immunodeficient
Immuno-OncologyFcResolv® huNOG Immunodeficient
Immuno-OncologyFcResolv® huNOG-EXL EA (Early Access) Immunodeficient
Immuno-OncologyhuNOG Immunodeficient
Immuno-OncologyhuPBMC-B2m-NOG Immunodeficient
Immuno-OncologyhuPBMC-NOG Immunodeficient
Immuno-OncologyICR scid Outbred or Mixed
Immuno-OncologyNCr nude Outbred or Mixed
Immuno-OncologyNIH nude rat Outbred or Mixed
Immuno-OncologyCIEA NOG mouse® Immunodeficient
Immuno-OncologyNMRI nude Outbred or Mixed
OncologyBALB/c nudeBALB/cAnNTacOutbred or Mixed
Cancer Type Animal Model Cell Line Citation(s)
View Citation(s)
Acute Myeloid Leukemia Black 6 (B6NTac) C1498
View Citation(s)J. Immunol. 1973 Jun;110(6):1470-5
Adenocarcinoma NCr nude KB-C2
View Citation(s)Cancer Lett. 2013 Jan 28
Adenocarcinoma NCr nude KB-3-1
View Citation(s)Cancer Lett. 2013 Jan 28
Astrocytoma NMRI nude U-251MG
View Citation(s)BMC Cancer 2012 Jun 13;12:242
B cell Lymphoma C3H 38C13
View Citation(s)Adv Hematol 2012;2012:701704
Eur. J. Immunol. 1977 Jul;7(7):413-7
Haematologica 2006 Feb;91(2):176-83
Bladder C.B-17 scid URO-MSC24
View Citation(s)Toxicol. Appl. Pharmacol. 2006 Oct 01;216(1):69-79
Bladder C.B-17 scid URO-ASC
View Citation(s)Toxicol. Appl. Pharmacol. 2006 Oct 01;216(1):69-79
Bladder NCr nude RT4
View Citation(s)Cancer Prev Res (Phila) 2008 Nov;1(6):439-51
Bladder BALB/c nude KU-19-19
View Citation(s)Cancer Gene Ther. 2007 Mar;14(3):279-86
Bladder C.B-17 scid UROtsa
View Citation(s)Toxicol. Appl. Pharmacol. 2006 Oct 01;216(1):69-79
Bladder C.B-17 scid URO-MSC52
View Citation(s)Toxicol. Appl. Pharmacol. 2006 Oct 01;216(1):69-79
Bladder Carcinoma C3H MBT-2
View Citation(s)Urol. Res. 1997;25(3):179-82
Cancer Res. 1977 Aug;37(8 Pt 2):2918-29
Bladder Carcinoma Black 6 (B6NTac) MB49
View Citation(s)J. Immunol. 1997 Jul 01;159(1):351-9
Breast NCr nude MDA-MB-231
View Citation(s)PLoS One . 2014 Jun 27
Breast NCr nude MCF-7
View Citation(s)Endocrinology . 1998 Apr
Breast NMRI nude M4A4-LM
View Citation(s)PLoS ONE 2010 Sep 30
Breast NMRI nude MDA-MB-435
View Citation(s)Neuro-oncology 2009 Apr
Breast NCr nude MCF-7
View Citation(s)Cell Rep . 2019 Mar 5
Breast NCr nude T47D
View Citation(s)J Biol Chem . 2016 Dec 16
Breast NCr nude MCF-7
View Citation(s)J Biol Chem . 2016 Dec 16
Breast NCr nude MDA-MB-231
View Citation(s)J Biol Chem . 2016 Dec 16
Breast BALB/c nude MCF-7/5C
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec
Breast NCr nude MDA-MB-231
View Citation(s)Neoplasia 2009 Jun
Breast ICR scid MDA-MB-468
View Citation(s)Mol. Cancer Ther. 2010 Jun
Breast NCr nude MDA-MB-231
View Citation(s)Sci Rep 2018 Feb 20;8(1):3321
Breast CIEA NOG mouse® MDA-MB-231
View Citation(s)Mol. Pharm. 2014 Nov 03;11(11):3988-95
Breast CIEA NOG mouse® SK-BR-3
View Citation(s)Mol. Pharm. 2014 Nov 03;11(11):3988-95
Breast CIEA NOG mouse® BT-474
View Citation(s)Mol. Pharm. 2014 Nov 03;11(11):3988-95
Breast NMRI nude M4A4-LM
View Citation(s)Int. J. Cancer 2007 Jul 01;121(1):165-74
Breast NMRI nude MCF-7
View Citation(s)Diagnostics (Basel) 2012 Oct 09;2(4):42-51
Breast NMRI nude SUM149PT
View Citation(s)Mol. Cancer Ther. 2016 04;15(4):583-92
Breast NMRI nude MCF-7
View Citation(s)BMC Med Imaging 2008 Oct 16;8:16
Breast NCr nude BT-20
View Citation(s)Mol. Cancer Ther. 2009 Mar;8(3):672-81
Breast NCr nude MCF-7
View Citation(s)Mol. Cancer Ther. 2009 Mar;8(3):672-81
Breast NCr nude MDA-MB-231
View Citation(s)Cancer Res. 2009 Aug 01;69(15):6223-31
Breast CIEA NOG mouse® MDA-MB-435_LUC
View Citation(s)Cancer Immunol Res 2015 Jul;3(7):764-76
Breast NCr nude MDA-MB-435
View Citation(s)Cancer Lett. 2013 Jul 01;334(2):263-73
Breast CIEA NOG mouse® MDA-MB-231
View Citation(s)PLoS ONE 2014;9(1):e86641
Breast NCr nude MDA-MB-231
View Citation(s)BMC Cancer 2010 Aug 13;10:427
Breast CIEA NOG mouse® MDA-MB-231
View Citation(s)Breast Cancer Res. 2012 Oct 25;14(5):R136
Breast NCr nude MDA-MB-231
View Citation(s)Cancer Res. 2010 Aug 01;70(15):6359-67
Breast NCr nude MCF 10A
View Citation(s)Oncogene 2010 Sep 16;29(37):5204-13
Breast NMRI nude MCF-7
View Citation(s)APMIS 2008 May;116(5):382-92
Breast Rag2/Il2rg Double Knockout (B6;B10) MDA-MB-231
View Citation(s)Neoplasia 2007 May;9(5):418-26
Breast NCr nude MDA-MB-435/LCC6
View Citation(s)Cancer Biol. Ther. 2011 May 01;11(9):826-38
Breast NCr nude MCF-7LU
View Citation(s)BMC Cancer 2010 Mar 22;10:107
Breast NCr nude MCF-7
View Citation(s)BMC Cancer 2010 Mar 22;10:107
Breast CIEA NOG mouse® MDA-MB-231
View Citation(s)Biomed. Pharmacother. 2006 Jul;60(6):273-6
Breast CIEA NOG mouse® MCF-7
View Citation(s)Biomed. Pharmacother. 2006 Jul;60(6):273-6
Breast NOD scid MDA-MB-231
View Citation(s)Neoplasia 2009 Jun;11(6):509-17, 2 p following 517
Breast CIEA NOG mouse® MDA-MB-231
View Citation(s)Cancer Lett. 2014 Jul 28;349(2):120-7
Breast NCr nude MDA-MB-231
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec;102(1-5):128-38
Breast BALB/c nude MCF-7/TAM2
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec;102(1-5):128-38
Breast BALB/c nude MCF-7/RAL2
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec;102(1-5):128-38
Breast BALB/c nude MCF-7/RAL1
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec;102(1-5):128-38
Breast BALB/c nude MCF-7/E2
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec;102(1-5):128-38
Breast BALB/c nude MCF-7
View Citation(s)J. Steroid Biochem. Mol. Biol. 2006 Dec;102(1-5):128-38
Breast NCr nude MDA-MB-231
View Citation(s)Br. J. Cancer 2007 Jul 02;97(1):58-64
Breast NCr nude MCF-7
View Citation(s)Br. J. Cancer 2007 Jul 02;97(1):58-64
Carcinoma NCr nude A-498
View Citation(s)Radiology 2009 Jun
Cervical NMRI nude HeLa
View Citation(s)Neuro-oncology 2009 Apr
Cervical CIEA NOG mouse® HeLa
View Citation(s)J Toxicol Sci 2009 Feb;34(1):123-7
Cholangiocarcinoma NMRI nude EGI-1
View Citation(s)World J. Gastroenterol. 2007 Sep 21;13(35):4761-70
Cholangiocarcinoma NMRI nude EGI-1
View Citation(s)World J. Gastroenterol. 2006 Mar 14;12(10):1583-90
Cholangiocarcinoma CIEA NOG mouse® RBE
View Citation(s)Cancer Sci. 2014 Jun;105(6):667-74
Cholangiocarcinoma CIEA NOG mouse® HuCCT1
View Citation(s)Cancer Sci. 2014 Jun;105(6):667-74
Clear Cell Carcinoma NCr nude Caki-1
View Citation(s)Radiology 2009 Jun
Colon NCr nude COLO 205
View Citation(s)Clin. Cancer Res. 2011 May 15
Colon NMRI nude HCT 116
View Citation(s)BMC Cancer 2010 Dec 12
Colon Swiss nude LS 174T
View Citation(s)Mol Cancer Ther . 2008 May
Colon NCr nude HT-29
View Citation(s)Gastroenterology . 2010 Oct
Colon NMRI nude HT-29
View Citation(s)Mol Cancer Ther . 2016 Mar
Colon CIEA NOG mouse® HCT 116
View Citation(s)Nitric Oxide 2015 Apr 30;46:102-13
Colon CIEA NOG mouse® HCT 116
View Citation(s)J. Immunol. 2015 Aug 15;195(4):1883-90
Colon CIEA NOG mouse® HCT116/venus
View Citation(s)Anal Bioanal Chem 2011 Jun;400(7):1895-904
Colon CIEA NOG mouse® HCT 116
View Citation(s)Oncol. Rep. 2013 Feb;29(2):464-8
Colon CIEA NOG mouse® Fucci-HCT116
View Citation(s)Mol. Cancer Res. 2013 Sep;11(9):973-85
Colon NOD scid SW620
View Citation(s)BMC Cancer 2012 Mar 20;12:96
Colon C.B-17 scid HT-29
View Citation(s)Cancer Gene Ther. 2012 Feb;19(2):126-34
Colon NMRI nude HCT 116
View Citation(s)Cancer Gene Ther. 2012 Feb;19(2):126-34
Colon NMRI nude COLO 205
View Citation(s)Mol. Cancer Ther. 2016 Mar;15(3):354-65
Colon NCr nude HCT 116
View Citation(s)J. Biol. Chem. 2007 Jul 27;282(30):21998-2010
Colon BALB/c nude T84
View Citation(s)PLoS ONE 2011 Mar 24;6(3):e17532
Colon BALB/c nude HT-29
View Citation(s)PLoS ONE 2011 Mar 24;6(3):e17532
Colon NCr nude LS 174T
View Citation(s)Int J Nanomedicine 2010 Oct 05;5:783-802
Colon NMRI nude HCT 116
View Citation(s)APMIS 2008 May;116(5):382-92
Colon NMRI nude HT-29
View Citation(s)J. Nucl. Med. 2016 Mar;57(3):437-43
Colon NMRI nude HCT 116
View Citation(s)J Transl Med 2010 Aug 23;8:80
Colon BALB/c nude HCT 116
View Citation(s)Mol. Cell 2010 Jun 11;38(5):689-99
Colon CIEA NOG mouse® HT-29
View Citation(s)Int. J. Oncol. 2008 Jan;32(1):153-9
Colon CIEA NOG mouse® LS 174T
View Citation(s)Int. J. Oncol. 2008 Jan;32(1):153-9
Colon CIEA NOG mouse® WiDr
View Citation(s)Int. J. Oncol. 2008 Jan;32(1):153-9
Colon CIEA NOG mouse® LoVo
View Citation(s)Int. J. Oncol. 2008 Jan;32(1):153-9
Colon CIEA NOG mouse® HCT 116
View Citation(s)Int. J. Oncol. 2008 Jan;32(1):153-9
Colon CIEA NOG mouse® COLO 320DM
View Citation(s)Int. J. Oncol. 2008 Jan;32(1):153-9
Colon C.B-17 scid LS 174T
View Citation(s)Clin. Cancer Res. 2009 Oct 01;15(19):6052-61
Colon Rag2 (C57BL/6) HT-29
View Citation(s)Mol. Cancer 2014 Nov 05;13:244
Colon CIEA NOG mouse® LS 174T
View Citation(s)Clin. Cancer Res. 2016 Jul 01;22(13):3286-97
Colon Adenocarcinoma Black 6 (B6NTac) MC-38
View Citation(s)Carcinogenesis 2005 Mar;26(3):513-23
Cancer Res. 1975 Sep;35(9):2434-9
Clin. Exp. Immunol. 2009 Jul;157(1):128-38
Nat Commun 2017 Feb 21;8:14572
J. Natl. Cancer Inst. 1976 Apr;56(4):871-3
PLoS ONE 2016;11(9):e0161779
J. Immunother. 2010 Sep;33(7):697-705
Colon Adenocarcinoma Black 6 (B6NTac) MC-38-CEA-1
View Citation(s)Cancer Res. 1991 Jul 15;51(14):3657-62
Colon Adenocarcinoma Black 6 (B6NTac) MC-38-CEA-2
View Citation(s)Clin. Exp. Immunol. 2009 Jul;157(1):128-38
Cancer Res. 1991 Jul 15;51(14):3657-62
Colon Adenocarcinoma BALB/c LM17
View Citation(s)Clin. Exp. Metastasis 1999;17(10):849-55
Colon Carcinoma BALB/c CT26
View Citation(s)Nat Commun 2017 Feb 21;8:14572
Cancer Res. 1980 Jul;40(7):2142-6
Proc. Natl. Acad. Sci. U.S.A. 2005 Jan 11;102(2):419-24
Cancer Res. 2013 Apr 15;73(8):2493-504
PLoS ONE 2016;11(9):e0161779
Carcinogenesis 2005 Mar;26(3):513-23
Colon Carcinoma BALB/c MC-26 (Colon 26, C-26)
View Citation(s)Cancer Res. 1975 Sep;35(9):2434-9
J. Nutr. 2005 Oct;135(10):2350-4
Proc. Natl. Acad. Sci. U.S.A. 2007 Jul 24;104(30):12457-61
Br. J. Cancer 2002 Aug 27;87(5):574-9
Colorectal carcinoma BALB/c 51BLim10
View Citation(s)Cancer Res. 1994 Dec 15;54(24):6477-83
Endometrial BALB/c nude AN3 CA
View Citation(s)Gynecol Oncol . 2014 Feb
Erythroleukemia Black 6 (B6NTac) FBL-3
View Citation(s)J. Immunol. 1976 Oct;117(4):1267-74
J. Natl. Cancer Inst. 1978 Jan;60(1):239-42
Cancer Res. 1968 Mar;28(3):434-9
Esophageal CIEA NOG mouse® KE4
View Citation(s)Cancer Sci. 2012 Jan;103(1):17-25
Fibrosarcoma ICR scid HT-1080
View Citation(s)J Cachexia Sarcopenia Muscle 2020 12;11(6):1813-1829
Fibrosarcoma NCr nude HT-1080
View Citation(s)Cancer Res. 2008 May 01;68(9):3350-60
Fibrosarcoma Black 6 (B6NTac) MC57G
View Citation(s)J. Immunol. 2004 Jan 15;172(2):929-36
Fibrosarcoma DBA/2 SaD2
View Citation(s)J. Immunol. 1978 Sep;121(3):1007-9
Fibrosarcoma Black 6 (B6NTac) MCA205
View Citation(s)Cancer Immunol Res 2015 May;3(5):526-35
Neoplasia 2015 Aug;17(8):661-70
Oncoimmunology 2013 Jun 01;2(6):e24786
Gallbladder NMRI nude CC-SW-1
View Citation(s)Oncotarget 2017 Oct 27;8(52):89736-89745
Gallbladder NMRI nude Sk-ChA-1
View Citation(s)Oncotarget 2017 Oct 27;8(52):89736-89745
Gallbladder NMRI nude MZ-ChA-1
View Citation(s)Oncotarget 2017 Oct 27;8(52):89736-89745
Gallbladder NMRI nude EGI-1
View Citation(s)Oncotarget 2017 Oct 27;8(52):89736-89745
Gallbladder NMRI nude TFK-1
View Citation(s)Oncotarget 2017 Oct 27;8(52):89736-89745
Gallbladder NMRI nude Mz-ChA-2
View Citation(s)Oncotarget 2017 Oct 27;8(52):89736-89745
Gallbladder NMRI nude Mz-ChA-2
View Citation(s)World J. Gastroenterol. 2007 Sep 21;13(35):4761-70
Gallbladder NMRI nude Mz-ChA-2
View Citation(s)World J. Gastroenterol. 2006 Mar 14;12(10):1583-90
Gallbladder BALB/c nude Mz-ChA-1
View Citation(s)Mol. Cancer Res. 2009 Oct;7(10):1704-13
Gastric Adenocarcinoma Black 6 (B6NTac) mGC8
View Citation(s)BMC Cancer 2006 Mar 14;6:57
Gastric Adenocarcinoma Black 6 (B6NTac) 424GC
View Citation(s)BMC Cancer 2006 Mar 14;6:57
J Transl Med 2011 Aug 22;9:140
Gastric Adenocarcinoma Black 6 (B6NTac) mGC3
View Citation(s)BMC Cancer 2006 Mar 14;6:57
J Transl Med 2011 Aug 22;9:140
Glioblastoma Swiss nude U 87 MG
View Citation(s)J Pharmacol Exp Ther. 2012 Nov
Glioblastoma NMRI nude U373 MG
View Citation(s)Neuro-oncology 2009 Apr
Glioblastoma C.B-17 scid LN229
View Citation(s)PLoS One . 2017 Apr 28
Glioblastoma NCr nude U 251 HF
View Citation(s)J Neurooncol. 2010 Jan
Glioblastoma NCr nude U 87 vIII
View Citation(s)J Neurooncol . 2011 Jan
Glioblastoma NCr nude T98G
View Citation(s)Neoplasia. 2009 Jan
Glioblastoma NCr nude U 87 MG
View Citation(s)J Evid Based Complementary Altern Med 2016 Jul 19;
Glioblastoma NMRI nude U 87 MG
View Citation(s)Nucl. Med. Biol. 2014 Mar;41(3):259-67
Glioblastoma NCr nude U 87 MG
View Citation(s)Biomaterials 2015 Oct;67:1-10
Glioblastoma ICR scid U 87 MG
View Citation(s)Biomaterials 2015 Oct;67:1-10
Glioblastoma NCr nude U 87 MG
View Citation(s)Int. J. Radiat. Oncol. Biol. Phys. 2012 Jan 01;82(1):483-91
Glioblastoma NMRI nude U 87 MG
View Citation(s)Neuro-oncology 2009 Apr;11(2):158-66
Glioblastoma NCr nude U 87 MG
View Citation(s)J Control Release 2007 Oct 08;122(3):356-63
Glioblastoma NOD scid LN-827
View Citation(s)Genes Cancer 2010 Aug;1(8):822-35
Glioma C.B-17 scid BT-40
View Citation(s)Oncotarget. 2015
Glioma C.B-17 scid BT-40
View Citation(s)Pediatr Blood Cancer. 2015 Oct
Glioma C.B-17 scid BT-40
View Citation(s)Clin Cancer Res. 2013 Dec 15
Glioma NCr nude A-172
View Citation(s)Neuro Oncol. 2009 Apr
Glioma Black 6 (B6NTac) GL261 (Glioma 261)
View Citation(s)Cancer Immunol. Immunother. 2015 Apr;64(4):447-57
Cancer Sci. 2006 Jun;97(6):546-53
PLoS ONE 2015;10(3):e0121314
Head and neck NCr nude FaDu
View Citation(s)Int J Hyperthermia 2010;26(5):485-98
Head and neck NMRI nude FaDu
View Citation(s)Clin. Cancer Res. 2008 Jul 15;14(14):4584-92
Head and neck NCr nude FaDu
View Citation(s)Cancer Res. 2000 Dec 15;60(24):6950-7
Head and neck NMRI nude FaDu
View Citation(s)J. Nucl. Med. 2016 Mar;57(3):437-43
Head and neck NMRI nude FaDu
View Citation(s)BMC Med Imaging 2016 Jan 14;16:5
Hepatocellular Carcinoma C3H Hca-F (HCa/16A3-F)
View Citation(s)World J. Gastroenterol. 2004 Feb 15;10(4):521-4
Carcinogenesis 2005 Mar;26(3):513-23
Hepatocellular carcinoma Black 6 (B6NTac) Hep-55.1C
View Citation(s)Hepatol. Res. 2016 Aug 08;
Mol. Carcinog. 1992;6(2):148-58
Hepatocellular Carcinoma C3H MH134 (MH134-TC)
View Citation(s)Cancer Immunol. Immunother. 1987;24(1):8-12
DNA Cell Biol. 2004 Sep;23(9):549-60
Cancer Res. 1985 Apr;45(4):1663-8
Hepatocellular Carcinoma Black 6 (B6NTac) Dt81Hepa1-6
View Citation(s)PLoS ONE 2017;12(2):e0171215
Hepatoma C3H Hepatoma 134 (MH-134)
View Citation(s)Cancer Res. 1985 Apr;45(4):1532-5
Hepatoma C3H Hepatoma 134 (MH-134)
View Citation(s)J. Natl. Cancer Inst. 1981 Oct;67(4):947-56
Proc. Natl. Acad. Sci. U.S.A. 2004 Apr 06;101(14):4990-5
Hepatoma C3H Hepatoma 129
View Citation(s)Cancer Res. 1987 Dec 01;47(23):6216-9
Kidney NCr nude 786-O
View Citation(s)Cancer Chemother Pharmacol . 2007 Apr
Kidney Scid-beige 786-O
View Citation(s)Radiology 2009 Jun;251(3):731-42
Kidney NMRI nude 786-O
View Citation(s)J. Virol. 2010 Jan;84(2):856-66
Leukemia NCr nude HL-60
View Citation(s)Blood . 1998 Apr 1
Leukemia CIEA NOG mouse® MT-2
View Citation(s)J. Virol. 2003 May
Leukemia CIEA NOG mouse® MT-4
View Citation(s)J. Virol. 2003 May
Leukemia CIEA NOG mouse® SLB-1
View Citation(s)J. Virol. 2003 May
Leukemia NOD scid NB4 
View Citation(s)Leukemia 2004 Mar
Leukemia CIEA NOG mouse® VR-ALL
View Citation(s)Oncotarget 2018 04 06;9(26):18341-18350
Leukemia CIEA NOG mouse® 43Tb(-)
View Citation(s)Retrovirology 2015 Nov 24;12:99
Leukemia CIEA NOG mouse® TL-OML
View Citation(s)Retrovirology 2015 Nov 24;12:99
Leukemia CIEA NOG mouse® SLB-1
View Citation(s)Retrovirology 2015 Nov 24;12:99
Leukemia NMRI nude ML-2
View Citation(s)Mol. Cancer Ther. 2010 Jun;9(6):1609-17
Leukemia NCr nude Jurkat
View Citation(s)In Vivo 25(4):603-7
Leukemia Scid-beige NALM-6
View Citation(s)Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35
Leukemia Scid-beige HL-60
View Citation(s)Leukemia 2012 Aug;26(8):1771-8
Leukemia CIEA NOG mouse® NB4 
View Citation(s)Biomed. Pharmacother. 2016 Apr;79:62-70
Leukemia C.B-17 scid Nalm-6-UM1
View Citation(s)Leuk. Res. 2008 Apr;32(4):625-32
Leukemia BALB/c nude HL-60
View Citation(s)J. Clin. Invest. 2007 Apr;117(4):1019-28
Leukemia CIEA NOG mouse® MV-4-11
View Citation(s)J. Pharmacol. Exp. Ther. 2015 Mar;352(3):579-89
Leukemia CIEA NOG mouse® MOLM-13
View Citation(s)J. Pharmacol. Exp. Ther. 2015 Mar;352(3):579-89
Leukemia CIEA NOG mouse® NB4 
View Citation(s)Leukemia 2004 Mar;18(3):442-8
Leukemia CIEA NOG mouse® TRL-01 
View Citation(s)Cancer Genet. Cytogenet. 2006 Aug;169(1):1-11
Leukemia CIEA NOG mouse® TL-OML
View Citation(s)J. Virol. 2003 May;77(9):5286-94
Leukemia CIEA NOG mouse® MT-1
View Citation(s)J. Virol. 2003 May;77(9):5286-94
Leukemia CIEA NOG mouse® ED-40515(-)
View Citation(s)J. Virol. 2003 May;77(9):5286-94
Leukemia Rag2 (BALB/c) MOLT-4
View Citation(s)MAbs 6(4):1000-12
Leukemia Black 6 (B6NTac) RBL-5
View Citation(s)J. Immunol. 1976 Oct;117(4):1267-74
J. Natl. Cancer Inst. 1978 Jan;60(1):239-42
J. Natl. Cancer Inst. 1977 Jun;58(6):1661-4
Leukemia C3H DA1-3b
View Citation(s)Leuk. Res. 1999 Apr;23(4):415-6
Blood 2004 Oct 01;104(7):2124-33
Gene Ther. 2000 Aug;7(15):1312-6
Leukemia Black 6 (B6NTac) RMA (RBL-5 subclone)
View Citation(s)Nature 2015 May 07;521(7550):99-104
J. Immunol. 2014 Feb 15;192(4):1577-86
J. Exp. Med. 1985 Dec 01;162(6):1745-59
Leukemia DBA/2 L-5178-Y
View Citation(s)J. Immunol. 2009 Feb 15;182(4):1940-53
Mutat. Res. 2017 Feb;814:1-6
Proc. Natl. Acad. Sci. U.S.A. 1996 Jun 25;93(13):6291-6
J. Immunol. 2004 Jul 15;173(2):1012-22
Leukemia BALB/c BCL1
View Citation(s)Blood 2012 Jun 28;119(26):6344-53
Biol. Blood Marrow Transplant. 2014 Aug;20(8):1089-103
Liver C.B-17 scid Hep 3B2.1-7
View Citation(s)PLoS ONE 2013;8(7):e68506
Liver C.B-17 scid Hep-G2
View Citation(s)PLoS ONE 2013;8(7):e68506
Liver NIH nude rat Huh-7.5
View Citation(s)Cancer Biol. Ther. 2009 May;8(9):856-65
Lung Rag2/Il2rg Double Knockout (B6;B10) NCI-H358
View Citation(s)J Biol Chem . 2011 Feb 11
Lung NCr nude A549
View Citation(s)J Biol Chem . 2011 Feb 11
Lung Rag2/Il2rg Double Knockout (B6;B10) A549
View Citation(s)J Biol Chem . 2011 Feb 11
Lung C.B-17 scid NCI-H1299
View Citation(s)Int J Nanomedicine. 2016
Lung NCr nude SK-MES-1
View Citation(s)Clin. Cancer Res. 2011 May 15
Lung NMRI nude NYH
View Citation(s)BMC Cancer 2010 Dec 12
Lung CIEA NOG mouse® NCI-H292
View Citation(s)Oncotarget 2017 Feb 07;8(6):9488-9499
Lung NMRI nude NCI-H1299
View Citation(s)Mol. Cancer Ther. 2016 04;15(4):583-92
Lung NMRI nude NCI-H727
View Citation(s)Nucl. Med. Biol. 2014 Mar;41(3):259-67
Lung NCr nude Calu-3
View Citation(s)Clin. Cancer Res. 2011 May 15;17(10):3157-69
Lung BALB/c nude HCC827
View Citation(s)Cancer Res. 2009 Feb 01;69(3):873-8
Lung BALB/c nude NCI-H358
View Citation(s)Cancer Res. 2009 Feb 01;69(3):873-8
Lung BALB/c nude A549
View Citation(s)Cancer Res. 2009 Feb 01;69(3):873-8
Lung Scid-beige A549
View Citation(s)Am. J. Respir. Cell Mol. Biol. 2008 Jun;38(6):671-8
Lung NCr nude NCI-H460
View Citation(s)Cancer Lett. 2013 Jan 28;328(2):307-17
Lung NCr nude NCI-H2126
View Citation(s)Comp. Med. 2009 Feb;59(1):37-45
Lung NCr nude NCI-H1975
View Citation(s)Comp. Med. 2009 Feb;59(1):37-45
Lung CIEA NOG mouse® QG-56
View Citation(s)Cancer Sci. 2012 Jan;103(1):17-25
Lung NMRI nude GLC19
View Citation(s)Neoplasia 2006 May;8(5):364-72
Lung C.B-17 scid LT 391-06
View Citation(s)J Transl Med 2007 Jun 25;5:29
Lung NMRI nude A549
View Citation(s)APMIS 2008 May;116(5):382-92
Lung NCr nude NCI-H460
View Citation(s)Clin Lung Cancer 2010 Nov 01;11(6):405-11
Lung NCr nude NCI-H358
View Citation(s)Clin Lung Cancer 2010 Nov 01;11(6):405-11
Lung NCr nude NCI-H1299
View Citation(s)Carcinogenesis 2010 Apr;31(4):687-94
Lung NCr nude A549
View Citation(s)Clin. Cancer Res. 2009 Aug 15;15(16):5136-44
Lung CIEA NOG mouse® T2821
View Citation(s)Cancers (Basel) 2015 May 22;7(2):876-907
Lung Rag2 (C57BL/6) A549
View Citation(s)Cancer Res. 2006 Jan 01;66(1):259-66
Lung Adenocarcinoma (transformed with HPV16) Black 6 (B6NTac) TC-1
View Citation(s)Nat. Med. 2016 Dec;22(12):1402-1410
Cancer Res. 1996 Jan 01;56(1):21-6
Proc. Natl. Acad. Sci. U.S.A. 2002 Dec 10;99(25):16232-6
Carcinogenesis 2005 Mar;26(3):513-23
Cancer Res. 2013 Apr 15;73(8):2493-504
Lung Carcinoma Black 6 (B6NTac) D122 (3LLD122)
View Citation(s)Int. J. Cancer 1984 Oct 15;34(4):567-73
Cancer Res. 1999 Aug 15;59(16):4035-41
Lung Carcinoma Black 6 (B6NTac) LL/2
View Citation(s)Carcinogenesis 2005 Mar;26(3):513-23
Cancer Lett. 1980 Nov;11(1):63-73
Lung Carcinoma BALB/c ASB-XIV
View Citation(s)Cancer Treat Rep 1983 Dec;67(12):1061-5
Cancer Immunol Res 2015 Dec;3(12):1333-43
Lung Carcinoma Black 6 (B6NTac) 3LL
View Citation(s)Cancer Lett. 1980 Nov;11(1):63-73
Blood 2010 Feb 18;115(7):1461-71
Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62
Cancer Res. 1999 Aug 15;59(16):4035-41
Lung Carcinoma BALB/c M109 (Madison Lung)
View Citation(s)In Vitro 1977 Apr;13(4):223-31
Cancer Treat Rep 1977 Nov;61(8):1459-70
Lung Squamous Cell Carcinoma DBA/2 KLN205
View Citation(s)Cancer Res. 1978 Jul;38(7):2084-90
Cell Rep 2016 May 17;15(7):1505-13
Clin. Cancer Res. 2004 Jan 01;10(1 Pt 1):293-300
In Vitro 1980 Oct;16(10):884-92
Lymphocytic Leukemia DBA/2 P1534
View Citation(s)Int. Arch. Allergy Appl. Immunol. 1969;35(1):20-34
Lymphocytic Leukemia DBA/2 P388
View Citation(s)Leukemia 1999 Oct;13(10):1592-600
Lymphoid Leukemia DBA/2 L1210
View Citation(s)J. Immunol. 2006 Jul 01;177(1):162-8
Immunology 2009 Sep;128(1 Suppl):e641-51
J. Natl. Cancer Inst. 1966 Mar;36(3):405-13, 415-21
Lymphoma CIEA NOG mouse® HUT78
View Citation(s)Blood 2014 Mar 06
Lymphoma CIEA NOG mouse® My-La
View Citation(s)Blood 2014 Mar 06
Lymphoma BALB/c nude BC-3
View Citation(s)J. Clin. Invest. 2007 Apr
Lymphoma CIEA NOG mouse® SNK6
View Citation(s)Clin. Cancer Res. 2014 Nov 01;20(21):5412-22
Lymphoma Scid-beige Raji
View Citation(s)Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35
Lymphoma ICR scid WSU-DLCL2
View Citation(s)J Hematol Oncol 2009 Feb 16;2:8
Lymphoma ICR scid WSU-DLCL2
View Citation(s)Clin. Cancer Res. 2009 Jun 15;15(12):4038-45
Lymphoma ICR scid WSU-FSCCL
View Citation(s)Clin. Cancer Res. 2009 Jun 15;15(12):4038-45
Lymphoma C.B-17 scid Namalwa
View Citation(s)Clin. Cancer Res. 2004 Feb 01;10(3):1100-11
Lymphoma CIEA NOG mouse® SNK6
View Citation(s)PLoS ONE 2013;8(5):e63566
Lymphoma CIEA NOG mouse® MJ
View Citation(s)Blood 2014 Mar 06;123(10):1499-511
Lymphoma CIEA NOG mouse® HH
View Citation(s)Blood 2014 Mar 06;123(10):1499-511
Lymphoma CIEA NOG mouse® ATN-1
View Citation(s)Blood 2014 Mar 06;123(10):1499-511
Lymphoma C.B-17 scid WSU-FSCCL
View Citation(s)Blood 2009 Jan 29;113(5):1062-70
Lymphoma C.B-17 scid Daudi
View Citation(s)Blood 2009 Jan 29;113(5):1062-70
Lymphoma CIEA NOG mouse® L-540
View Citation(s)Cancer Sci. 2005 Aug;96(8):466-73
Lymphoma CIEA NOG mouse® L-428
View Citation(s)Cancer Sci. 2005 Aug;96(8):466-73
Lymphoma CIEA NOG mouse® KM-H2
View Citation(s)Cancer Sci. 2005 Aug;96(8):466-73
Lymphoma CIEA NOG mouse® HDLM-2
View Citation(s)Cancer Sci. 2005 Aug;96(8):466-73
Lymphoma CIEA NOG mouse® TY-1
View Citation(s)Cancer Sci. 2006 Dec;97(12):1381-7
Lymphoma CIEA NOG mouse® BCBL-1
View Citation(s)Cancer Sci. 2006 Dec;97(12):1381-7
Lymphoma Black 6 (B6NTac) C6VL
View Citation(s)J. Immunol. 2004 Jan 15;172(2):929-36
J. Immunol. 1982 Nov;129(5):2293-300
Lymphoma BALB/c A20 (A-20)
View Citation(s)Blood 2009 Nov 12;114(20):4477-85
Adv Hematol 2012;2012:701704
Blood 2010 Jul 15;116(2):226-38
J. Immunol. 1979 Feb;122(2):549-54
Lymphoma Black 6 (B6NTac) EL-4
View Citation(s)Science 1971 Jan 08;171(3966):75-7
J. Immunol. 2004 Jan 15;172(2):929-36
J. Immunol. 2011 Apr 15;186(8):5004-11
Br. J. Cancer 1950 Dec;4(4):372-9
Lymphoma Black 6 (B6NTac) E.G7-OVA
View Citation(s)Cell 1988 Sep 09;54(6):777-85
J. Immunol. 2011 Apr 15;186(8):5004-11
Lymphoma BALB/c PU5-1.8 (PU5-1R, TIB-61)
View Citation(s)J. Exp. Med. 1976 Jun 01;143(6):1528-33
Cancer Res. 1977 Feb;37(2):546-50
Lymphosarcoma C3H 6C3HED
View Citation(s)Cancer Res. 1998 Jun 15;58(12):2594-600
Lymphosarcoma BALB/c LSTRA
View Citation(s)Leuk. Res. 2003 Apr;27(4):351-7
Cancer Res. 1968 Mar;28(3):434-9
EMBO J. 1982;1(12):1579-82
J. Immunol. 1976 Oct;117(4):1267-74
Mol. Cell. Biol. 1984 Dec;4(12):2705-13
Lymphosarcoma BALB/c P1798
View Citation(s)Mol. Cell. Endocrinol. 1980 Feb;17(2):95-102
Lymphosarcoma DBA/2 MDW3
View Citation(s)Int. J. Cancer 1989 May 15;43(5):828-36
J. Natl. Cancer Inst. 1981 Jan;66(1):129-39
Int. J. Cancer 1984 Nov 15;34(5):709-16
Lymphosarcoma DBA/2 MDAY-D2
View Citation(s)Blood 2000 Jul 15;96(2):691-8
J. Cell Biol. 1995 Dec;131(6 Pt 2):1849-55
J. Natl. Cancer Inst. 1980 May;64(5):1221-30
Int. J. Cancer 1984 Nov 15;34(5):709-16
Mammary Adenocarcinoma FVB DB-7(fvb2)
View Citation(s)Clin. Exp. Metastasis 2005;22(1):47-59
Mammary Adenocarcinoma BALB/c SM1
View Citation(s)Proc. Natl. Acad. Sci. U.S.A. 1998 Aug 18;95(17):10067-71
Cancer Res. 1992 Oct 15;52(20):5732-7
Mammary Adenocarcinoma BALB/c LM3
View Citation(s)Carcinogenesis 2005 Mar;26(3):513-23
Int. J. Oncol. 1997 Sep;11(3):489-96
Mammary Adenocarcinoma FVB H6O5
View Citation(s)Oncogene 2012 May 24;31(21):2614-26
Proteomics 2010 Nov;10(21):3800-10
Mammary Adenocarcinoma BALB/c D2F2
View Citation(s)J. Leukoc. Biol. 1985 Nov;38(5):573-85
Br. J. Cancer 1992 May;65(5):641-8
Cancer Res. 2010 Oct 01;70(19):7431-41
Cancer Gene Ther. 2012 Apr;19(4):282-91
Mammary Adenocarcinoma BALB/c TUBO
View Citation(s)J. Immunol. 2000 Nov 01;165(9):5133-42
Mol. Ther. 2013 Jan;21(1):91-100
Mammary Adenocarcinoma DBA/2 T1699
View Citation(s)Int. J. Cancer 1984 Jan 15;33(1):73-7
Mammary Adenocarcinoma BALB/c D2.0R
View Citation(s)Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 1993 Jan;11(1):103-12
Mammary Adenocarcinoma C3H C3HBA
View Citation(s)Eur J Cancer 1975 Dec;11(12):891-901
Mammary Adenocarcinoma FVB Met-1(fvb2)
View Citation(s)Clin. Exp. Metastasis 2005;22(1):47-59
Mammary Adenocarcinoma BALB/c 4T1
View Citation(s)Breast Cancer Res. 2000;2(5):331-4
Nature 2015 May 07;521(7550):99-104
Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 1999 Mar;17(2):163-70
Proc. Natl. Acad. Sci. U.S.A. 2007 Oct 02;104(40):15735-40
Mammary Adenocarcinoma BALB/c MC4-L3
View Citation(s)Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma Black 6 (B6NTac) E0771
View Citation(s)Cell Rep 2014 Mar 27;6(6):992-9
Dis Model Mech 2015 Mar;8(3):237-51
Proc. Soc. Exp. Biol. Med. 1951 Jun;77(2):358-62
Anticancer Res. 25(6B):3905-15
Nat Commun 2016 Jul 13;7:12258
Mammary Adenocarcinoma BALB/c MC4-L2
View Citation(s)Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma BALB/c D2A1
View Citation(s)Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 1993 Jan;11(1):103-12
Mammary Adenocarcinoma BALB/c MC4-L1
View Citation(s)Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma BALB/c 4T07
View Citation(s)Int. J. Cancer 1991 Feb 01;47(3):466-72
Carcinogenesis 2005 Mar;26(3):513-23
Cancer Res. 1992 Mar 15;52(6):1399-405
Br. J. Cancer 1987 Nov;56(5):561-9
Mammary Adenocarcinoma DBA/1 dbrB
View Citation(s)Proc. Soc. Exp. Biol. Med. 80(4):696-7
Mammary Adenocarcinoma Black 6 (B6NTac) Adenocarcinoma 755 (CA755)
View Citation(s)Int. J. Radiat. Oncol. Biol. Phys. 4(5-6):395-400
Oncotarget 2013 Oct;4(10):1829-35
Mammary Adenocarcinoma BALB/c MC4-L5
View Citation(s)Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma C3H CaD2
View Citation(s)Proc. Natl. Acad. Sci. U.S.A. 1977 Oct;74(10):4610-4
Cancer Lett. 1992 Jan 31;61(3):263-7
Mammary Adenocarcinoma FVB Tgl-1
View Citation(s)Gene Ther. 2006 Oct;13(19):1391-402
Cancer Res. 1998 May 01;58(9):1965-71
Mammary Adenocarcinoma BALB/c 66C14
View Citation(s)Breast Cancer Res. 2000;2(5):331-4
J. Cell. Biochem. 1988 Feb;36(2):129-36
Mammary Carcinoma BALB/c EMT6
View Citation(s)J. Natl. Cancer Inst. 1972 Sep;49(3):735-49
Mast Cell Leukemia DBA/2 P815
View Citation(s)J. Immunol. 1984 Jun;132(6):3218-25
Curr Protoc Immunol 2001 May;Chapter 20:Unit 20.4
J. Immunol. 2006 Jul 01;177(1):162-8
Differentiation 1986;32(2):157-64
Melanoma NCr nude WM9
View Citation(s)J. Natl. Cancer Inst. 2002 Jul 03
Melanoma C.B-17 scid SK-MEL-5
View Citation(s)Cancer Res. 2012 Oct 01
Melanoma C.B-17 scid A-375
View Citation(s)Cancer Res. 2012 Oct 01
Melanoma C.B-17 scid A-375
View Citation(s)Clin. Cancer Res. 2007 Dec 01;13(23):7217-23
Melanoma ICR scid DB-1
View Citation(s)Cancer Res. 2000 Jul 01;60(13):3532-6
Melanoma BALB/c nude SK-MEL-31
View Citation(s)Cell 2008 Feb 08;132(3):363-74
Melanoma BALB/c nude SK-MEL-28
View Citation(s)Cell 2008 Feb 08;132(3):363-74
Melanoma NMRI nude G-361
View Citation(s)Mol. Cancer Ther. 2016 Mar;15(3):354-65
Melanoma NMRI nude A-375
View Citation(s)Mol. Cancer Ther. 2016 Mar;15(3):354-65
Melanoma C.B-17 scid WM1617
View Citation(s)Cancer Res. 2012 Oct 01;72(19):5111-8
Melanoma CIEA NOG mouse® HMY-1
View Citation(s)Oncol. Rep. 2005 Sep;14(3):633-7
Melanoma CIEA NOG mouse® G-361
View Citation(s)Oncol. Rep. 2005 Sep;14(3):633-7
Melanoma CIEA NOG mouse® A-375
View Citation(s)Oncol. Rep. 2005 Sep;14(3):633-7
Melanoma CIEA NOG mouse® A2058
View Citation(s)Oncol. Rep. 2005 Sep;14(3):633-7
Melanoma Scid-beige Mel493
View Citation(s)Cancer Immunol. Immunother. 2009 Feb;58(2):209-20
Melanoma Scid-beige MeE384
View Citation(s)Cancer Immunol. Immunother. 2009 Feb;58(2):209-20
Melanoma C.B-17 scid A-375
View Citation(s)Biochem. Pharmacol. 2009 Aug 15;78(4):344-54
Melanoma DBA/2 Cloudman S91 (Clone M-3)
View Citation(s)Int. J. Radiat. Oncol. Biol. Phys. 1987 Nov;13(11):1725-33
Prostaglandins 1983 Sep;26(3):449-56
Mol. Ther. 2003 Apr;7(4):498-505
Br. J. Cancer 1988 Jan;57(1):64-9
Melanoma Black 6 (B6NTac) B16F10
View Citation(s)Cancer Res. 1975 Jan;35(1):218-24
Cancer Res. 1999 Aug 15;59(16):4035-41
Nat. Med. 2016 Dec;22(12):1402-1410
Cancer Cell Int. 2013;13:75
Nature 2015 May 07;521(7550):99-104
Life Sci. 2002 Jan 04;70(7):791-8
Mol. Ther. 2003 Apr;7(4):498-505
PLoS ONE 2013;8(6):e66081
Melanoma Black 6 (B6NTac) B16
View Citation(s)Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62
Cancer Lett. 1984 Aug;24(1):57-63
J. Natl. Cancer Inst. 1970 Oct;45(4):789-800
Carcinogenesis 2005 Mar;26(3):513-23
J. Cell Biol. 1969 Nov;43(2):263-74
Mesothelioma Scid-beige LRK1A
View Citation(s)Am. J. Respir. Cell Mol. Biol. 2008 Jun
Mesothelioma Scid-beige MesoSA1
View Citation(s)Am. J. Respir. Cell Mol. Biol. 2008 Jun;38(6):671-8
Mesothelioma CIEA NOG mouse® ACC-MESO-1
View Citation(s)J. Surg. Res. 2011 Oct;170(2):e197-209
Mesothelioma BALB/c AB12
View Citation(s)Int. J. Cancer 1992 Dec 02;52(6):881-6
Oncol. Rep. 2012 Aug;28(2):707-13
Mol. Ther. 2002 Aug;6(2):210-8
Mesothelioma Black 6 (B6NTac) AE17
View Citation(s)Oncol. Rep. 2012 Aug;28(2):707-13
Myeloma C.B-17 scid INA-6
View Citation(s)Blood 2005 Jul 15;106(2):713-6
Myeloma CIEA NOG mouse® RPMI-8226
View Citation(s)Oncotarget 2013 Aug;4(8):1230-40
Myeloma CIEA NOG mouse® NCI-H929
View Citation(s)Oncotarget 2013 Aug;4(8):1230-40
Myeloma CIEA NOG mouse® U266B1
View Citation(s)Biochem. Biophys. Res. Commun. 2004 Jan 09;313(2):258-62
Myeloma C.B-17 scid INA-6
View Citation(s)Clin. Cancer Res. 2009 Dec 01;15(23):7144-52
Myeloma C.B-17 scid INA-6
View Citation(s)Blood 2009 Jul 09;114(2):371-9
Myeloma CIEA NOG mouse® U266B1
View Citation(s)Cancer Sci. 2004 Jul;95(7):564-8
Myeloma CIEA NOG mouse® KMM-1
View Citation(s)Cancer Sci. 2004 Jul;95(7):564-8
Myeloma Black 6 (B6NTac) 5T33
View Citation(s)Br. J. Cancer 1992 Dec;66(6):1088-93
Neuroblastoma C.B-17 scid NGP
View Citation(s)J Pediatr Hematol Oncol . 2014 Jan
Neuroblastoma C.B-17 scid SY5Y
View Citation(s)J Pediatr Hematol Oncol . 2014 Jan
Neuroblastoma C.B-17 scid SK-N-AS
View Citation(s)J. Pediatr. Surg. 2013 Jan;48(1):39-46
Neuroblastoma C.B-17 scid NB-1691
View Citation(s)J. Pediatr. Surg. 2013 Jan;48(1):39-46
Neuroblastoma C.B-17 scid CHLA-20
View Citation(s)J. Pediatr. Surg. 2013 Jan;48(1):39-46
Neuroblastoma BALB/c nude SK-N-AS
View Citation(s)Oncogene 2009 Jan 29;28(4):479-91
Neuroblastoma NMRI nude SK-N-FI 
View Citation(s)Hum. Gene Ther. 2013 Aug;24(8):766-75
Neuroblastoma Scid-beige SK-N-SH
View Citation(s)J. Virol. 2011 Dec;85(24):13114-23
Osteogenic Sarcoma C3H HE 10734
View Citation(s)Cancer Chemother Rep 1964 Jan;34:11-7
Osteosarcoma Scid-beige MNNG-HOS
View Citation(s)Oncogene. 2009 Sep 24
Osteosarcoma C.B-17 scid SaOS-LM7
View Citation(s)PLoS One. 2017
Osteosarcoma C.B-17 scid LM7
View Citation(s)Mol Ther . 2009 Oct
Osteosarcoma BALB/c K7M2
View Citation(s)Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 2000;18(3):261-71
Ovarian NCr nude A2780
View Citation(s)Am. J. Pathol. 2009 Apr;174(4):1504-14
Ovarian NMRI nude A2780
View Citation(s)PLoS ONE 2013;8(12):e85126
Ovarian NMRI nude A2780
View Citation(s)APMIS 2008 May;116(5):382-92
Ovarian NMRI nude A2780
View Citation(s)PLoS ONE 2010 Sep 24;5(9):e12965
Ovarian ICR scid OVCAR-3
View Citation(s)J Labelled Comp Radiopharm 2009 Dec 01;52(14):583-590
Ovarian BALB/c nude TOV-21G
View Citation(s)Br. J. Cancer 2015 Feb 03;112(3):504-13
Ovarian BALB/c nude TOV-112D
View Citation(s)Br. J. Cancer 2015 Feb 03;112(3):504-13
Ovarian NCr nude OVCAR-3
View Citation(s)J. Natl. Cancer Inst. 2002 Jul 03;94(13):1010-9
Ovarian NMRI nude A2780cis
View Citation(s)Mol. Cancer Ther. 2016 04;15(4):583-92
Ovarian NMRI nude A2780
View Citation(s)Mol. Cancer Ther. 2010 Jun;9(6):1609-17
Ovarian NCr nude A2780/CP70
View Citation(s)J Ovarian Res 2011 Jun 22;4:9
Ovarian Carcinoma Black 6 (B6NTac) MOVCAR 5612
View Citation(s)J Ovarian Res 2010 Oct 19;3:24
J. Biol. Chem. 2012 Aug 24;287(35):29873-86
Ovarian Carcinoma Black 6 (B6NTac) MOVCAR 5447
View Citation(s)J. Biol. Chem. 2012 Aug 24;287(35):29873-86
J Ovarian Res 2010 Oct 19;3:24
Ovarian Carcinoma Black 6 (B6NTac) ID8 (MOSEC)
View Citation(s)Anticancer Res. 26(4B):2785-9
Carcinogenesis 2000 Apr;21(4):585-91
J. Immunol. 2014 Nov 15;193(10):5327-37
Gynecol. Oncol. 2016 Aug;142(2):332-40
Gynecol. Oncol. 2008 Feb;108(2):385-94
Ovarian Carcinoma Black 6 (B6NTac) MOVCAR 5009
View Citation(s)J Ovarian Res 2010 Oct 19;3:24
J. Biol. Chem. 2012 Aug 24;287(35):29873-86
Pancreatic NCr nude BxPC-3
View Citation(s)Clin. Cancer Res. 2011 May 15
Pancreatic NCr nude Capan-1
View Citation(s)Clin. Cancer Res. 2011 May 15
Pancreatic NCr nude MIA PaCa-2
View Citation(s)Clin. Cancer Res. 2009 Nov 01;15(21):6519-28
Pancreatic CIEA NOG mouse® PL45
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic CIEA NOG mouse® PANC-1
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic CIEA NOG mouse® MIA PaCa-2
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic CIEA NOG mouse® Capan-2
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic CIEA NOG mouse® Capan-1
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic CIEA NOG mouse® BxPC-3
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic CIEA NOG mouse® AsPC-1
View Citation(s)Int. J. Oncol. 2007 Oct;31(4):741-51
Pancreatic NMRI nude MIA PaCa-2
View Citation(s)Br. J. Cancer 2008 Jul 08;99(1):110-7
Pancreatic NCr nude PANC-1
View Citation(s)Clin. Cancer Res. 2009 Aug 15;15(16):5136-44
Pancreatic NCr nude BxPC-3
View Citation(s)Clin. Cancer Res. 2009 Aug 15;15(16):5136-44
Pancreatic NMRI nude MIA PaCa-2
View Citation(s)Int J Pharm 2013 Jan 30;441(1-2):499-506
Pancreatic NMRI nude L3.6pl
View Citation(s)World J. Gastroenterol. 2008 Jun 21;14(23):3681-92
Pancreatic NMRI nude HPAF-II
View Citation(s)World J. Gastroenterol. 2008 Jun 21;14(23):3681-92
Pancreatic NCr nude Capan-1
View Citation(s)Clin. Cancer Res. 2015 Nov 15;21(22):5131-8
Pancreatic Adenocarcinoma Black 6 (B6NTac) Panc02
View Citation(s)Clin Transl Sci 2008 Dec;1(3):228-39
Cancer Res. 1984 Feb;44(2):717-26
Eur Surg Res 2011;47(2):98-107
J. Immunother. 2010 Sep;33(7):697-705
J. Immunol. 2010 Oct 01;185(7):4063-71
J Vis Exp 2014 Sep 27;(91):51677
Int J Gastrointest Cancer 2001;29(1):37-46
Curr. Mol. Med. 2012 Mar;12(3):331-41
Pancreatic Adenocarcinoma Black 6 (B6NTac) MT5
View Citation(s)Gut 2016 Oct 21;
Pancreatic Ductal Adenocarcinoma Black 6 (B6NTac) 6606PDA
View Citation(s)Eur Surg Res 2011;47(2):98-107
Cell Biosci 2015;5:51
BMC Cancer 2011 Jan 28;11:40
Plasmacytoma BALB/c J558
View Citation(s)J. Exp. Med. 2001 Nov 05;194(9):1339-48
Plasmacytoma BALB/c J558
View Citation(s)Nat Commun 2017 Feb 21;8:14572
J. Natl. Cancer Inst. 1972 Sep;49(3):735-49
Carcinogenesis 2005 Mar;26(3):513-23
Plasmacytoma C3H C1.18.4 (C1-18)
View Citation(s)Exp. Cell Res. 1970 Apr;60(1):61-77
Plasmacytoma C3H X5563
View Citation(s)Exp. Cell Res. 1970 Apr;60(1):61-77
Cancer Immunol. Immunother. 1987;24(1):8-12
Plasmacytoma BALB/c ADJ/PC6
View Citation(s)Anticancer Drugs 2005 Jul;16(6):653-7
Immunology 1982 Nov;47(3):503-10
Plasmacytoma BALB/c RPC5.4
View Citation(s)Science 1971 Jan 08;171(3966):75-7
Pleiomorphic Cell Sarcoma Black 6 (B6NTac) Lewis Sarcoma T241
View Citation(s)Anticancer Res. 3(4):263-8
Cancer Res. 2011 Nov 01;71(21):6676-83
Prostate NMRI nude PC-82
View Citation(s)J Nucl Med . 2007 Jan
Prostate NMRI nude PC-310
View Citation(s)J Nucl Med . 2007 Jan
Prostate NMRI nude PC-295
View Citation(s)J Nucl Med . 2007 Jan
Prostate Rag2 (C57BL/6) PC-3
View Citation(s)ACS Cent Sci . 2019 Apr 24
Prostate C.B-17 scid VCaP
View Citation(s)Clin. Cancer Res. 2018 May 15
Prostate NCr nude PC-3
View Citation(s)Mol Imaging Biol 2016 06;18(3):402-10
Prostate NCr nude LNCaP
View Citation(s)Mol Imaging Biol 2016 06;18(3):402-10
Prostate NCr nude PC-3
View Citation(s)Sci Rep 2018 Feb 20;8(1):3321
Prostate C.B-17 scid LNCaP
View Citation(s)Clin. Cancer Res. 2018 May 15;24(10):2408-2416
Prostate C.B-17 scid PC-3
View Citation(s)Biol. Pharm. Bull. 2014;37(6):1029-34
Prostate C.B-17 scid LNCaP C4-2B
View Citation(s)Neoplasia 2008 Apr;10(4):371-80
Prostate NMRI nude DU145
View Citation(s)Am J Nucl Med Mol Imaging 2014;4(4):311-23
Prostate NMRI nude PC-3
View Citation(s)Am J Nucl Med Mol Imaging 2014;4(4):311-23
Prostate NMRI nude PC346-DCC-K
View Citation(s)EBioMedicine 2018 Jan;27:182-186
Prostate NMRI nude PC3-MM2
View Citation(s)Clin. Cancer Res. 2009 Sep 01;15(17):5396-403
Prostate NMRI nude PC3-MM2
View Citation(s)PLoS ONE 2012;7(3):e32871
Prostate NMRI nude PC-346C
View Citation(s)Eur. Urol. 2015 Jun;67(6):1177-1185
Prostate NCr nude PC-3
View Citation(s)PLoS ONE 2010 Mar 31;5(3):e9885
Prostate NOD scid DU145
View Citation(s)Gene Ther. 2010 Aug;17(8):1042-51
Prostate C.B-17 scid PC-3
View Citation(s)J. Exp. Clin. Cancer Res. 2009 Jan 12;28:6
Prostate ICR scid PC-3
View Citation(s)Bioconjug. Chem. 2008 Oct;19(10):2040-8
Prostate BALB/c nude LNCaP
View Citation(s)BMC Genomics 2009 Oct 15;10:476
Prostate ICR scid PC-3
View Citation(s)Am. J. Pathol. 2009 Sep;175(3):1255-69
Prostate ICR scid PC-3
View Citation(s)Nucl. Med. Biol. 2009 Oct;36(7):789-800
Prostate NMRI nude PC-3
View Citation(s)APMIS 2008 May;116(5):382-92
Prostate C.B-17 scid LAPC-4
View Citation(s)Prostate 2013 May;73(7):754-62
Prostate C.B-17 scid LNCaP
View Citation(s)Prostate 2013 May;73(7):754-62
Prostate ICR scid PC-3
View Citation(s)Cancer Biother. Radiopharm. 2006 Apr;21(2):155-66
Prostate NCr nude LNCaP
View Citation(s)PLoS ONE 2007 Mar 07;2(3):e267
Prostate C.B-17 scid PC-3
View Citation(s)Neoplasia 2008 Apr;10(4):371-80
Prostate NCr nude PC-3
View Citation(s)Oncogene 2015 Apr 09;34(15):1928-37
Prostate NCr nude DU145
View Citation(s)Oncogene 2015 Apr 09;34(15):1928-37
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C1D
View Citation(s)J. Biol. Chem. 2001 Apr 06;276(14):11204-13
Cancer Res. 1997 Aug 15;57(16):3325-30
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C2
View Citation(s)Cancer Res. 1997 Aug 15;57(16):3325-30
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C1A
View Citation(s)Cancer Res. 1997 Aug 15;57(16):3325-30
J. Biol. Chem. 2001 Apr 06;276(14):11204-13
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C1
View Citation(s)Proc. Natl. Acad. Sci. U.S.A. 1997 Jul 22;94(15):8099-103
Cancer Res. 1997 Aug 15;57(16):3325-30
Prostate Adenocarcinoma Black 6 (B6NTac) RM-1
View Citation(s)Prostate 2009 Nov 01;69(15):1613-23
J. Steroid Biochem. Mol. Biol. 1995 May;52(5):403-13
Nat Commun 2013;4:1795
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C3
View Citation(s)Cancer Res. 1997 Aug 15;57(16):3325-30
Renal Adenocarcinoma BALB/c RenCa
View Citation(s)Cancer Res. 1986 Jul;46(7):3358-63
Carcinogenesis 2005 Mar;26(3):513-23
Mol. Ther. 2003 Apr;7(4):498-505
J. Immunol. 2006 Aug 15;177(4):2575-83
Reticulum Cell Sarcoma Black 6 (B6NTac) M5076 (M5)
View Citation(s)Eur. J. Cancer 1996 Oct;32A(11):2011-8
Cancer Res. 1981 Apr;41(4):1271-80
Sarcoma BALB/c Meth A Sarcoma (METH-A)
View Citation(s)Cell Prolif. 2001 Aug;34(4):211-22
Cell Prolif. 2003 Apr;36(2):87-100
Mol. Cell. Biol. 1989 Aug;9(8):3385-92
Proc. Natl. Acad. Sci. U.S.A. 1995 Mar 14;92(6):2219-23
Sarcoma 129S6 F244
View Citation(s)Immunology 2013 Jun;139(2):265-74
Cancer Immunol Res 2017 Feb;5(2):106-117
Oncoimmunology 2013 Jun 01;2(6):e24786
Squamous Cell Carcinoma C3H SCC-7
View Citation(s)Cancer Lett. 2012 Apr 28;317(2):199-206
Cancer Res. 2016 Aug 15;76(16):4661-72
Br. J. Cancer 1982 Jul;46(1):109-16
Oncol Lett 2013 Dec;6(6):1799-1803
Squamous Cell Carcinoma Black 6 (B6NTac) mEERL
View Citation(s)J. Virol. 2008 Mar;82(5):2493-500
Oncotarget 2016 Apr 26;7(17):24194-207
Head Neck 2015 Mar;37(3):327-35
Arch. Otolaryngol. Head Neck Surg. 2007 May;133(5):495-502
Stomach C.B-17 scid MKN28
View Citation(s)Clin. Cancer Res. 2006 May 15
Stomach NMRI nude MKN45
View Citation(s)Clin. Cancer Res. 2006 May 15;12(10):3137-44
Stomach NCr nude NCI-N87
View Citation(s)Clin. Cancer Res. 2015 Nov 15;21(22):5131-8
Stomach ICR scid NCI-N87
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Stomach Rag2/Il2rg Double Knockout (B6;B10) NCI-N87
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Stomach Rag2/Il2rg Double Knockout (B6;B10) MKN74
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Stomach ICR scid MKN74
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Stomach ICR scid MKN45
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Stomach Rag2/Il2rg Double Knockout (B6;B10) MKN45
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Stomach Rag2/Il2rg Double Knockout (B6;B10) AGS
View Citation(s)Stem Cells 2009 May;27(5):1006-20
Testicular Carcinoma Black 6 (B6NTac) M5480
View Citation(s)J. Natl. Cancer Inst. 1975 Sep;55(3):623-31


Category Model Strain Name (Stock No.) Strain Type
Oncology Black 6 (B6NTac) C57BL/6NTac Inbred
Oncology B6JBom C57BL/6JBomTac Inbred
Oncology BALB/c BALB/cAnNTac Inbred
Oncology BALB/c Bom BALB/cJBomTac Inbred
Oncology C3H C3H/HeNTac Inbred
Oncology DBA/2 DBA/2NTac Inbred
Oncology FVB FVB/NTac Inbred
Oncology DBA/1 DBA/1JBomTac Inbred
Oncology 129S6 C3H/HeNTac Inbred
Oncology B6.SJL B6.SJL-Ptprca  Adoptive Transfer
Oncology β-actin-luc - Model 11977 β-actin-luc Adoptive Transfer
Oncology Rag2/OT-I Rag2/OT-I TCR Transgenic
Oncology Rag2/OT-II (11490) Rag2/OT-II TCR Transgenic
Immuno-Oncology Jh (C57BL/6) Jh (C57BL/6) Immunodeficient
Immuno-Oncology Rag2 - Model RAGN12 Rag2 Knockout Immunodeficient
Immuno-Oncology Rag2/Il2rg Double Knockout Rag2/Il2rg Knockout Immunodeficient
Immuno-Oncology Abb (H2-Ab1) - Model ABBN12 Abb Knockout Immunodeficient
Immuno-Oncology Abb (H2-Ab1) - Model 4026 Abb Knockout with Ptprca Immunodeficient
Immuno-Oncology B2m (β2m) B2m Knockout Immunodeficient
Immuno-Oncology Abb/B2m Abb/B2m Knockout Immunodeficient
Immuno-Oncology Fcer1g (FcRγ) - Model 583 Fcer1g (FcRγ) Immunodeficient
Immuno-Oncology Fcgr2b (FcγRII) - Model 580 Fcgr2b (FcyRII) Immunodeficient
Immuno-Oncology Jh (BALB/c) Jh (BALB/c)  Immunodeficient
Immuno-Oncology Fcer1g - Model 584 Fcer1g (FcRγ) Immunodeficient
Immuno-Oncology Fcgr2b - Model 579 Fcgr2b (FcγRII) Immunodeficient
Immuno-Oncology Rag2 - Model 601 Rag2 Knockout Immunodeficient
Immuno-Oncology CIEA BRG mouse Rag2/Il2rg Knockout (BRG) Immunodeficient
Oncology NFκB-RE-luc NFκB-RE-luc Reporter
Oncology HLA-A2.1 C57BL/6 or CB6F1 Transgenic
Oncology HLA-A11 C57BL/6 or CB6F1 Transgenic
Oncology HLA-A1 C57BL/6 or CB6F1 Transgenic
Oncology HLA-A24 C57BL/6 or CB6F1 Transgenic
Oncology HLA-B7 C57BL/6 or CB6F1 Transgenic
Oncology HLA-B44 C57BL/6 or CB6F1 Transgenic
Oncology Abb Knockout/Transgenic HLA-DR4 C57BL/6 Transgenic
Oncology Stat1 Knockout N/A Transgenic
Oncology TSG-p53® N/A Transgenic
Oncology Pirc Rat N/A Transgenic
Oncology Invasive Lobular Breast Cancer Model N/A  
Oncology Brca1-Associated Breast Cancer Model N/A  
Oncology Floxed Ink4a/Arf Mouse N/A  
Oncology Floxed p53 Mouse N/A  
Immuno-Oncology NOG-EXL (hGM-CSF/hIL-3 NOG) 13395 Immunodeficient
Immuno-Oncology hIL-2 NOG 13440 Immunodeficient
Immuno-Oncology hIL-15 NOG 13683 Immunodeficient
Immuno-Oncology hIL-6 NOG 13686 Immunodeficient
Immuno-Oncology B2m-NOG 14957 Immunodeficient
Immuno-Oncology FcResolv® NOG 19164 Immunodeficient
Immuno-Oncology FcResolv® hIL-15 NOG 19220 Immunodeficient
Immuno-Oncology FcResolv® NOG-EXL 21552 Immunodeficient
Immuno-Oncology C.B-17 scid   Immunodeficient
Immuno-Oncology scid-beige   Immunodeficient
Immuno-Oncology huNOG-EXL SA (Standard Access)   Immunodeficient
Immuno-Oncology huNOG-EXL EA (Early Access)   Immunodeficient
Immuno-Oncology FcResolv® huNOG   Immunodeficient
Immuno-Oncology FcResolv® huNOG-EXL EA (Early Access)   Immunodeficient
Immuno-Oncology huNOG   Immunodeficient
Immuno-Oncology huPBMC-B2m-NOG   Immunodeficient
Immuno-Oncology huPBMC-NOG   Immunodeficient
Immuno-Oncology ICR scid   Outbred or Mixed
Immuno-Oncology NCr nude   Outbred or Mixed
Immuno-Oncology NIH nude rat   Outbred or Mixed
Immuno-Oncology CIEA NOG mouse®   Immunodeficient
Immuno-Oncology NMRI nude   Outbred or Mixed
Oncology BALB/c nude BALB/cAnNTac Outbred or Mixed

Oncology and Immuno-Oncology Mouse & Rat Model Portfolio

Humanized Immune System Mice

Humanized immune system models are widely used in preclinical immuno-oncology research. Selecting the right strain for your project starts by determining which human cell types are relevant to your specific disease.


Featured Models

Syngeneic Tumor Mouse Models & Research Tools

Syngeneic tumor mouse models are widely used for immuno-oncology as they offer a translatable in vivo system with normal immune function for testing immune-modulating therapeutics. Taconic offers a comprehensive toolbox for syngeneic studies, ranging from common inbred strains to advanced genetically engineered models for more sophisticated experiments.

Image of Scientist grabbing Model

Immunodeficient Mice & Rats

Immunodeficient mice and rats are used as hosts for xenografts and for immune system humanization. Taconic offers a range of strains from nude mice to super immunodeficient models to facilitate studies using both human cell lines and patient-derived xenografts as well as sophisticated humanized immune system models for immuno-oncology studies.

Image of Scientist grabbing Model

Featured Models

NOG Mouse Portfolio

The CIEA NOG mouse® is a versatile and widely used super immunodeficient model with broad global adoption by researchers in both academia and industry. The NOG mouse is the model of choice for xenografts, particularly difficult to engraft cell lines and patient-derived xenografts, as well as immune system humanization.

Image of Scientist grabbing Model

Featured Models

Spontaneous Tumor Mouse & Rat Models

Spontaneous tumor mouse and rat models are models in which specific mutations have been genetically introduced to provoke spontaneous tumor development. Spontaneous tumor models can be challenging to work with, as tumor development is often inconsistent from animal to animal and may only take place in aged animals. Taconic offers several mouse and rat models capable of developing tumors de novo in the appropriate tissue. These models can be tailored to reflect the human microenvironment and are suitable for a range of applications, including tumorigenesis studies, tumor prevention studies, and testing novel drug candidates.

Image of Scientist grabbing Model

Transgenic HLA Mouse Models

Transgenic mice that express human HLA molecules can be used for a variety of cancer immunotherapy studies. Key applications include the evaluation of HLA-restricted CTL epitope responses in vivo, determining the immunogenicity of novel cancer vaccines, and testing the expansion and response of chimeric antigen receptor T cells.

Image of Scientist grabbing Model

Featured Models

Cell Line Databases

Xenograft Cell Line Database 

Taconic Biosciences has been a source of immunodeficient mice and rats for use in xenograft studies for more than 40 years. Use the database of published references to help select the most appropriate model for your study.

Syngeneic Cell Line Reference Database

Taconic Biosciences offers both inbred mice and GEMs on defined backgrounds. These models are widely used for syngeneic tumor studies in which mouse tumor cells are engrafted into hosts from the same genetic background. Use the database of published references to identify tumor cell lines and associated background strains that are most appropriate for your study.

Frequently Asked Questions (FAQs) About Oncology & Cancer Models

Both types of experimental systems have great utility in immuno-oncology research, and the most appropriate model depends on your specific research question. Syngeneic tumor mouse models maintain a fully-intact immune system, have a tumor that is genetically-matched with immune system and stroma, but contain a mouse tumor and mouse immune system, which will vary from the human versions. Humanized immune system (HIS) mice contain modified immune systems but have the potential for greater translatability by studying human tumors and human immune cells together. Additional factors to consider are whether your test article recognizes mouse and/or human targets, whether the immune cell of interest is present in a humanized mouse model, and whether you are performing large-scale screening (a syngeneic tumor model may be faster and more cost-effective) versus investigating mechanistic questions for a late-stage drug candidate (a humanized immune system model may be most appropriate).

While the use of mice has provided important insight into our understanding of normal and pathophysiological processes, the biological differences between mice and humans are limiting factors in the translation of many immunotherapies to the clinical setting. There is thus a growing need for mouse models that more faithfully recapitulate important features of human biology. Towards this goal, various methods have been developed to humanize mice, and these models are quickly becoming an essential tool for basic and applied research. Humanized immune system mice have provided critical insights into development of cancer immunotherapies due to their ability to model the interaction between the human immune system and cancer in vivo. Genetically humanized mice which express a human target protein may be useful when the mouse and human versions of a protein differ significantly. Finally, microbiome humanization is starting to illuminate questions such as why do some patients respond to immunotherapies while others do not.

There are many variations of humanized immune system mice, and the best model for a particular study must consider the immune cell(s) of interest, the tumor of interest, the likely study window needed and more. At a high level, the two most commonly used humanization methods in these models are CD34+ hematopoietic stem cells (HSC) engraftment , which involves the transplantation of human hematopoietic stem cells that engraft and differentiate into various types of human immune cells, and PBMC engraftment, in which human peripheral blood mononuclear cells are injected. These methods are combined with a range of host strains, and the resulting models differ in the cell types that engraft, immune function of the engrafted human cells, as well as timelines for development and the useful study window. Thus use of the appropriate system is dependent upon the scientific question under investigation.

Taconic's Field Applications Scientists can help you determine which humanized model will best suit your research goals.

Humanized models based on engraftment of CD34+ HSCs require more lead time for the humanized immune system to fully develop, but also offer a longer study window, though this exact window depends on the host strain. These models also tend to develop a wider range of functional human immune cells in the periphery. Taconic's humanized huNOG and huNOG-EXL mice are engrafted with human CD34+ HSCs which promote the development of a humanized model with human lymphocytes that are present in peripheral blood, bone marrow, thymus, and spleen. While these models can be used for long-term studies, not all human immune cell types are present or completely functional.

Taconic's humanized huPBMC mice are engrafted with human peripheral blood mononuclear cells (PBMCs). These models are primarily thought of as T cell models. While they are relatively easy and fast to development, they have a much shorter lifespan and can only be used for studies on the order of weeks, not multiple months. However, these models can be particularly useful for graft versus host disease (GvHD) studies.

 

First, select a syngeneic cell line based on the type of cancer that will be investigated. Second, navigate to Taconic's syngeneic cell line database and filter based on cancer type. This database will also display what background strain(s) are available in which to study the chosen cancer. Order the tumor cell line from your preferred cell line vendor and determine the exact type of mouse model needed for this study.

There is a wide range of humanized immune system models, and the appropriate combination of a host strain, engraftment method and cell source can often provide a model which offers one or multiple human immune cells. Options are available to study the following types of human immune cells:

  • T cells, including CD4+, CD8+ and Treg
  • NK cells
  • Dendritic cells, including mDCs and pDCs
  • Monocytes, including classical, non-classical and intermediate
  • Macrophages
  • Granulocytes
  • Eosinophils
  • Basophils
  • Tumor-associated macrophages (TAMs)
  • Tumor-infiltrating lymphocytes (TILs)
  • Myeloid-derived suppressor cells (MDSCs)

Custom Solutions for Oncology and Immuno-Oncology Research

Taconic Biosciences' globally-recognized scientific project managers support your custom model design project from design to delivery. Each custom model design project develops along an agile framework, letting you reassess and retarget your model fluidly as new data becomes available. You can pause or postpone projects at any time, or even "back up" project milestones via cryopreservation.

 

Model Generation Solutions & Breeding Services

  • Model Acquisition
  • Transition Mutant to Model
  • Scaled Breeding
  • Specialized Services
  • Distribution

Colony Management Solutions

  • Extensive Health Standard Options
  • True Gnotobiotic Profiles
  • Genetic Monitoring Programs
  • Scientific Leadership & Success Team
  • Custom Solutions for Every Partner

Featured Oncology and Immuno-Oncology Resources

White Paper

Syngeneic Mouse Models for Preclinical Immuno-Oncology Research

Discover how syngeneic mouse models support immuno-oncology research. Learn key differences, applications, and considerations for successful tumor studies.

On-Demand Webinar

An Introduction to Humanized Immune System (HIS) Mice

Learn the fundamentals of Humanized Immune System (HIS) mice, including NOG models, humanization methods, and their applications in immuno-oncology and beyond.

White Paper

An Introduction to Humanized Immune System Mouse Models

Discover how humanized immune system mouse models recapitulate key aspects of human biology. Explore methods, benefits, and strain selection for your research.

On-Demand Webinar

Bridging the Gap: Advancing Prostate Cancer Therapies with huNOG Xenograft Models

In this exclusive webinar, learn how Taconic’s huNOG mouse model has been successfully used in xenograft studies to model prostate cancer, including to test FDA-approved therapeutics.

Get In Touch

Book a complimentary consultation or get support for an existing order

If you need immediate assistance, please contact Customer Service:

Taconic Corporate Offices

Email: info@taconic.com

Phone: +1 (518) 697-3900

273 Hover Ave., Germantown, NY 12526

North American Customer Service

Email: info@taconic.com

Phone:
+1 (518) 697-3915 

Toll-free:
+1 (888) 822-6642


Hours:
(Monday - Friday): 7 a.m. - 6 p.m. ET

European Customer Service

Email: info@taconic.com

Phone (Europe and Denmark):
+45 70 23 04 05 

Phone (Germany):
+49 214 50 68 023 

Hours: (Monday - Friday):
7 a.m. - 5 p.m. CET